Prosecution Insights
Last updated: April 19, 2026

Examiner: MCCORMICK, CATHERINE LYNN

Tech Center 1600 • Art Units: 1638

This examiner grants 52% of resolved cases

Performance Statistics

51.7%
Allow Rate
-8.3% vs TC avg
63
Total Applications
+16.7%
Interview Lift
1345
Avg Prosecution Days
Based on 29 resolved cases, 2023–2026

Rejection Statute Breakdown

4.5%
§101 Eligibility
28.3%
§102 Novelty
44.6%
§103 Obviousness
15.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17926970 ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE Non-Final OA The Regents of the University of California
17972875 PREPARATION METHOD FOR ANIMAL MODEL OF ALZHEIMER'S DISEASE AND ANIMAL MODEL OF ALZHEIMER'S DISEASE PREPARED BY THE SAME Non-Final OA KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
18255951 TREATMENT OF CONGENITAL STATIONARY NIGHT BLINDNESS USING GENE THERAPY Non-Final OA INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM)
18039840 Antibody Delivery Non-Final OA AC Immune SA
18560053 RECOMBINANT TERT-ENCODING VIRAL GENOMES AND VECTORS Non-Final OA TELOMERE THERAPEUTICS SL
17623738 CELL CULTURE SCAFFOLD, PRODUCTION METHOD THEREOF, SCAFFOLD PRODUCTION KIT, AND PRODUCTION METHOD OF CELL CULTURE PRODUCT Non-Final OA KINKI UNIVERSITY
17625442 SPECIFIC MARKER FOR IDENTIFYING T CELLS SPECIFICALLY ATTACKING CANCER CELLS Non-Final OA Kotai Biotechnologies, Inc.
18548807 HB-EGF GENE THERAPY FOR DIABETES Non-Final OA KAGOSHIMA UNIVERSITY
18208576 METHOD AND APPARATUS FOR REDUCING PROBABILITY OF ICE NUCLEATION DURING PRESERVATION OF BIOLOGICAL MATTER IN ISOCHORIC SYSTEMS Non-Final OA BioChoric, Inc.
18036066 RECOMBINANT ADENO-ASSOCIATED VIRUSES WITH ENHANCED LIVER TROPISM AND USES THEREOF Non-Final OA BEIJING SOLOBIO GENETECHNOLOGY CO., LTD
18250873 TISSUE SCAFFOLDS Non-Final OA JD BIOMEDICAL SOLUTIONS LTD.
18181952 COMPOSITIONS AND METHODS FOR RECOMBINANT PARVOVIRUS PRODUCTION Final Rejection AAVNERGENE INC.
18177938 Regulation of Gene Expression by Aptamer-Mediated Accessibility of Polyadenylation Signals Non-Final OA MeiraGTx Gene Regulation Limited
18042517 CODON OPTIMIZED RPGRORF15 GENES AND USES THEREOF Non-Final OA 4D MOLECULAR THERAPEUTICS INC.
18021364 COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEREDITARY ANGIOEDEMA Non-Final OA Orchard Therapeutics (Europe) Limited
17977476 MESENCHYMAL STEM CELLS FOR THE PREVENTION AND TARGETED TREATMENT OF CANCER AND OTHER DISORDERS Final Rejection MAM Holdings of West Florida, L.L.C.
17996910 ARTIFICIAL EXPRESSION CONSTRUCTS FOR SELECTIVELY MODULATING GENE EXPRESSION IN NEOCORTICAL LAYER 5 GLUTAMATERGIC NEURONS Non-Final OA ALLEN INSTITUTE
17919890 SUPER-ENCHANCERS FOR RECOMBINANT GENE EXPRESSION IN CHO CELLS Non-Final OA LEK Pharmaceuticals d.d.
17995969 iPSC INDUCTION Final Rejection Roslin Technologies Limited

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month